|Articles|August 5, 2020
Catalent
Author(s)Catalent Pharma Solutions
Catalent’s next-generation cell line development technology, GPEx® Boost, leverages GPEx platform improvements and a glutamine synthase knock-out CHO cell line, providing the same stability and proven technology of traditional GPEx technology with enhanced benefits, including increased titer for even the most difficult-to-express proteins, improved cell growth and viability, and fewer process steps, resulting in reduced timelines.
Catalent
14 Schoolhouse Road Somerset, NJ 08873 USA
Tel. +1.888.765.8846
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
Coya Raises $11.1 Million to Advance Immunomodulatory ALS Program
2
AstraZeneca’s $15 Billion Investment Deepens China R&D and Manufacturing Footprint
3
FAQ: What You Need to Know About Agentic AI in Drug Discovery
4
HHS Releases New Guidance on Lowering Prescription Drug Prices Through DTC Programs
5